EUVIMEDEUVIMED entdecken
Crossref

Clinical features of polymyalgia rheumatica patients in Japan: Analysis of real-world data from 2015 to 2020

Yoshiya Tanaka, Shinichi Tanaka, Toshiya Takahashi, Naoto Kato

Modern Rheumatology · 2023

DOI: 10.1093/mr/road026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yoshiya Tanaka und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Polymyalgia Rheumatica. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess clinical features in patients with polymyalgia rheumatica (PMR) in Japan by the International Classification of Disease (ICD)-10 code assignment.

Methods

Demographics, treatment patterns, and concomitant diseases (identified using ICD-10 code only) in patients who were assigned the PMR ICD-10 code M35.3 at least once between 1 January 2015 and 31 December 2020 were aggregated from a nationwide medical information database owned by the Health, Clinic, and Education Information Evaluation Institute.

Results

The cumulative number of patients with PMR was 6325 (mean [standard deviation] age, 74.3 [11.4] years; male:female, 1:1.3). Most patients were >50 years (96.5%) with >33% between 70 and 79 years. Glucocorticoids were prescribed in ∼54% of patients within 30 days of PMR code assignment. All other drug types were prescribed in <5% of patients. Hypertension, diabetes mellitus, rheumatoid arthritis, and osteoporosis were noted in >25% and giant cell arteritis in 1% of patients. During the study period, 4075 patients were newly assigned the PMR code and 62% were prescribed glucocorticoids within 30 days.

Conclusions

This is the first retrospective real-world data analysis describing the clinical features of PMR in a large patient population from Japan. Further studies of prevalence, incidence, and clinical features are warranted in patients with PMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisPolymyalgia RheumaticaHumansMaleFemaleAgedRetrospective StudiesJapanGlucocorticoids

Stichwörter der Autor:innen

Concomitant medicationJapanglucocorticoidpolymyalgia rheumaticareal-world data

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
  • Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
  • Specialty Care Medical, Sanofi K.K., Tokyo, Japan.

Zitieren

APA

Tanaka, Y., Tanaka, S., Takahashi, T., & Kato, N. (2023). Clinical features of polymyalgia rheumatica patients in Japan: Analysis of real-world data from 2015 to 2020. Modern Rheumatology. https://doi.org/10.1093/mr/road026

Vancouver

Tanaka Y, Tanaka S, Takahashi T, Kato N. Clinical features of polymyalgia rheumatica patients in Japan: Analysis of real-world data from 2015 to 2020. Modern Rheumatology. 2023. doi:10.1093/mr/road026

BibTeX
@article{Tanaka2023,
  author = {Tanaka, Yoshiya and Tanaka, Shinichi and Takahashi, Toshiya and Kato, Naoto},
  title = {Clinical features of polymyalgia rheumatica patients in Japan: Analysis of real-world data from 2015 to 2020},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/road026}
}
Kostenlos starten →